Deal with Health Canada to Triple Aphria’s Medical Cannabis Production

This deal will more than triple Aphria’s production capacity of medical cannabis from 9,000 kg to 30,000 kg annually.

Canadian marijuana company, Aphria, (TSX: APH and US OTC: APHQF) said on Tuesday that its medical marijuana production is expected to increase more than threefold after receiving a license amendment from Health Canada.

The license will provide Aphria with additional production space of 200,000 square feet, as part of its third-tier expansion at its facility in Leamington, Ontario.

“This marks the completion of the third part of our four-part expansion plan and is another exciting milestone for Aphria,” said Vic Neufeld, Chief Executive Office of Aphria.

The first crop cultivated and produced at third-phase expansion will be available for sale in the last week of May.